Anika Therapeutics (ANIK) Appoints Richard Hague To Role Of Chief Commercial Officer

Industry Veteran to Oversee Further Global Expansion of Commercial Platform, Strengthening of Commercial Partnerships, and Development of Direct Commercial Capability

BEDFORD, MASSACHUSETTS – OCTOBER 29, 2015 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, announced the appointment of Richard Hague as Chief Commercial Officer.

Mr. Hague, who brings over three decades of commercial leadership experience in the life sciences sector, will report directly to Anika's President and Chief Executive Officer, Charles H. Sherwood, Ph.D. In this role, Mr. Hague holds primary responsibility for leading the Company's global commercial strategy, including opening new geographic markets for the Company's products, and strengthening the Company's reach to end users, through both commercial partnerships and the development of a direct sales capability.

"Over the past two decades, Anika has demonstrated a proven track record of conceptualizing, developing, manufacturing, and partnering a broad range of innovative life science products, enabling us to build a stable, profitable business," said Dr. Charles H. Sherwood, President and Chief Executive Officer. "For our next phase of growth, we believe opening new markets around the world for our products, and reaching patients in new ways, through strong partnerships and direct sales capabilities, will be vital. We are confident Richard's commercial leadership experience will complement our differentiated product portfolio, extensive network of business partners, and promising pipeline of orthopedic therapies to achieve this mission, and ultimately drive future demand and build long-term value."

Prior to assuming his position at Anika, Mr. Hague served as Vice President, Sales and Marketing, for TEI Medical, where he was responsible for driving revenue growth, building the sales and marketing teams, and implementing strategies to drive national account and federal and private payer acceptance of the company's technology platform. He previously was Vice President Sales, Marketing and Commercial Operations at Sanofi Biosurgery, where he led the build out of the global sales and marketing team and oversaw all commercial activities in the U.S. for the company's Cell Therapy and Regenerative Medicine business. Mr. Hague's prior experience also includes leadership positions at Genzyme Biosurgery as Senior Director and Head of U.S. Sales, and Northeast Regional Sales Director. Mr. Hague holds a B.S. in Marketing from the University of Connecticut.

"I am excited to join a company like Anika with its proven success in developing and building market-leading products and its robust pipeline of first-in-class orthopedic and regenerative medicine products," said Mr. Hague. "I look forward to partnering with the Anika team to further advance the Company's already solid commercial platform and pave the way for future success."

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Mass. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing clinically meaningful therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing and commercializing more than 20 products, in markets across the globe, based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio is comprised of marketed (ORTHOVISC® and MONOVISC®) and pipeline (CINGAL® and HYALOFAST® in the U.S.) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. For more information about Anika, please visit http://www.anikatherapeutics.com.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.